-
Get the latest information and research on osteoporosis.
-
Find treatment, guidance and advice on living with osteoporosis.
-
Share your experience and get involved. Joining the conversation is the first step to ending osteoporosis and broken bones.
National Osteoporosis Foundation (NOF) Announces New President and Vice President
July 27, 2005 (Washington, DC) – The National Osteoporosis Foundation (NOF) announces that, as of July 21, Ethel S. Siris, MD, has begun her term as NOF President. Additionally, NOF announced the election of Sundeep Khosla, MD, to the newly created office of Vice President. Dr. Siris’ term follows the completion of three years of distinguished service as NOF President by Dr. Bess Dawson-Hughes of the USDA Human Nutrition Research Center on Aging, Tufts University, who remains on the NOF Board of Trustees as Immediate Past President.
Dr. Siris is the Madeline C. Stabile Professor of Clinical Medicine in the Department of Medicine, College of Physicians and Surgeons of Columbia University, and the Director of the Toni Stabile Osteoporosis Center of the Columbia University Medical Center, New York Presbyterian Hospital, both in New York City. Dr. Siris received her AB degree from Radcliffe College, Harvard University and her medical degree from the College of Physicians and Surgeons of Columbia University. An endocrinologist, she has worked as a clinician, clinical investigator, and medical educator in the area of metabolic bone diseases. Dr. Siris was elected to the NOF Board of Trustees in 1994 and has most recently served as Chair of the Science and Research Committee.
Dr. Khosla serves as Professor of Medicine and Research Chair in the Division of Endocrinology, Metabolism, and Nutrition, Mayo Clinic College of Medicine. He is also Director of the Endocrine Research Theme at Mayo. Dr. Khosla received his A.B. degree from Harvard College and his M.D. from Harvard Medical School. His research interests include mechanisms of postmenopausal and age-related bone loss as well as sex steroid regulation of bone metabolism. Dr. Khosla was elected to the NOF Board of Trustees in 2002.
The latest
Last week, a Food and Drug Administration (FDA) Panel voted that the risks of calcitonin salmon outweigh the benefits for the treatment of postmenopausal osteoporosis. The panel joined health authorities around the world in reviewing the drug’s safety after two recent studies showed slightly higher rates of cancer among patients taking calcitonin. The panel voted against continued use of the drug by a narrow majority, pointing out that it has not been found very effective in preventing bone fractures.
In today's Washington Post article "Calcium and Vitamin D findings show that caring for your bones can be compilicated," NOF's senior clinical director, Dr. Felicia Cosman helps clear up some of the confusion around the recent and conflicting research on calcium and vitamin D. She says: "It’s confusing, even for doctors. But there’s a common thread: None of the heart or kidney risks were associated with calcium from food."
CIRCA, the leading international buyer of fine jewelry, diamonds and watches, announced a new partnership with NOF at a Generations of Strength luncheon at the Friars Club in New York City on February 26. To kick-off the partnership, CIRCA’s Acting CEO Mary L. Forté presented NOF Executive Director and CEO Amy Porter with a check for $25,000, to support NOF’s mission.
Explore by tag
